Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis. Mult Scler Relat Disord. 2020;44:102260. https://doi.org/10.1016/j.msard.2020.102260.
Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54–9. https://doi.org/10.1001/archneurol.2008.505.
Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009;66(8):967–71. https://doi.org/10.1001/archneurol.2009.135.
Yeh EA, Weinstock-Guttman B, Ramanathan M, Ramasamy DP, Willis L, Cox JL, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009;132(Pt 12):3392–400. https://doi.org/10.1093/brain/awp278.
Article CAS PubMed Google Scholar
Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603–13. https://doi.org/10.1056/NEJMoa067597.
Article CAS PubMed Google Scholar
Hittle M, Culpepper WJ, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, et al. Population-based estimates for the prevalence of multiple sclerosis in the united states by race, ethnicity, age, sex, and geographic region. JAMA Neurol. 2023;80(7):693–701. https://doi.org/10.1001/jamaneurol.2023.1135.
Article PubMed PubMed Central Google Scholar
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21. https://doi.org/10.1177/1352458520970841.
Article PubMed PubMed Central Google Scholar
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.
Fadda G, Brown RA, Longoni G, Castro DA, O’Mahony J, Verhey LH, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2018;2(3):191–204. https://doi.org/10.1016/S2352-4642(18)30026-9.
Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 2023;22(8):750–68. https://doi.org/10.1016/S1474-4422(23)00148-5.
Benson LA, Healy BC, Gorman MP, Baruch NF, Gholipour T, Musallam A, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014;3(2):186–93. https://doi.org/10.1016/j.msard.2013.06.004.
Article CAS PubMed Google Scholar
Chitnis T, Aaen G, Belman A, Benson L, Gorman M, Goyal MS, et al. Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain. 2020;143(9):2733–41. https://doi.org/10.1093/brain/awaa199.
Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, et al. Risk of persistent disability in patients with pediatric-onset multiple sclerosis. JAMA Neurol. 2021;78(6):726–35. https://doi.org/10.1001/jamaneurol.2021.1008.
Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, et al. Multiple sclerosis progression and relapse activity in children. JAMA Neurol. 2024;81(1):50–8. https://doi.org/10.1001/jamaneurol.2023.4455.
Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147–61. https://doi.org/10.1093/brain/awac016.
Article PubMed PubMed Central Google Scholar
McKay KA, Manouchehrinia A, Berrigan L, Fisk JD, Olsson T, Hillert J. Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis. JAMA Neurol. 2019;76(9):1028–34. https://doi.org/10.1001/jamaneurol.2019.1546.
Article PubMed PubMed Central Google Scholar
Ruano L, Branco M, Portaccio E, Goretti B, Niccolai C, Patti F, et al. Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: an Italian collaborative study. Mult Scler. 2018;24(9):1234–42. https://doi.org/10.1177/1352458517717341.
Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008;70(20):1891–7. https://doi.org/10.1212/01.wnl.0000312276.23177.fa.
Article CAS PubMed Google Scholar
Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moiola L, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010;75(13):1134–40. https://doi.org/10.1212/WNL.0b013e3181f4d821.
Article CAS PubMed Google Scholar
Portaccio E, Bellinvia A, Razzolini L, Pasto L, Goretti B, Niccolai C, et al. Long-term cognitive outcomes and socioprofessional attainment in people with multiple sclerosis with childhood onset. Neurology. 2022;98(16):e1626–36. https://doi.org/10.1212/WNL.0000000000200115.
Article CAS PubMed Google Scholar
Carotenuto A, Moccia M, Costabile T, Signoriello E, Paolicelli D, Simone M, et al. Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis. Sci Rep. 2019;9(1):18074. https://doi.org/10.1038/s41598-019-54153-7.
Article CAS PubMed PubMed Central Google Scholar
Banwell B, Giovannoni G, Hawkes C, Lublin F. Editors’ welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord. 2013;2(2):65–7. https://doi.org/10.1016/j.msard.2012.12.001.
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–37. https://doi.org/10.1016/S1474-4422(11)70023-0.
Article CAS PubMed Google Scholar
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–60. https://doi.org/10.1016/S1474-4422(09)70021-3.
Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, et al. Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016;22(10):1297–305. https://doi.org/10.1177/1352458515616701.
Szilasiova J, Mikula P, Rosenberger J, Fedicova M, Gdovinova Z, Urban P, et al. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss. Mult Scler. 2021;27(13):2023–30. https://doi.org/10.1177/1352458521998039.
Article CAS PubMed Google Scholar
Giovannoni G, Bermel R, Phillips T, Rudick R. A brief history of NEDA. Mult Scler Relat Disord. 2018;20:228–30. https://doi.org/10.1016/j.msard.2017.07.011.
Prosperini L, Mancinelli C, Haggiag S, Cordioli C, De Giglio L, De Rossi N, et al. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(3):271–7. https://doi.org/10.1136/jnnp-2019-322348.
Comments (0)